晚期子宫内膜癌患者静脉血栓栓塞的发生率和时机。

IF 5.7 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Obstetrics and gynecology Pub Date : 2025-06-18 DOI:10.1097/aog.0000000000005978

Josie D Llanora,Shitanshu Uppal,Hannah D McLaughlin

{"title":"晚期子宫内膜癌患者静脉血栓栓塞的发生率和时机。","authors":"Josie D Llanora,Shitanshu Uppal,Hannah D McLaughlin","doi":"10.1097/aog.0000000000005978","DOIUrl":null,"url":null,"abstract":"Patients with advanced endometrial cancer (EC) are at risk for venous thromboembolism (VTE), though risk by treatment phase remains unclear. This single-institution retrospective study evaluated 84 patients receiving neoadjuvant chemotherapy (NACT, n=34) or adjuvant chemotherapy (n=50) for stage III-IV EC. Overall VTE incidence was 27.4% (95% CI, 18.8-38.0%). Among patients receiving NACT, VTE occurred in 14.3% during NACT and in 16.7% during ongoing chemotherapy. Postoperative and adjuvant treatment rates were less than 10.0%. Khorana score was a poor predictor of VTE, with 52.0% of intermediate-risk patients developing VTE. These findings highlight the need for improved VTE risk-reduction strategies, including larger studies to evaluate optimization of risk stratification and VTE prophylaxis during systemic therapy for advanced EC.","PeriodicalId":19483,"journal":{"name":"Obstetrics and gynecology","volume":"75 1","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Incidence and Timing of Venous Thromboembolism in Patients With Advanced Endometrial Cancer.\",\"authors\":\"Josie D Llanora,Shitanshu Uppal,Hannah D McLaughlin\",\"doi\":\"10.1097/aog.0000000000005978\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Patients with advanced endometrial cancer (EC) are at risk for venous thromboembolism (VTE), though risk by treatment phase remains unclear. This single-institution retrospective study evaluated 84 patients receiving neoadjuvant chemotherapy (NACT, n=34) or adjuvant chemotherapy (n=50) for stage III-IV EC. Overall VTE incidence was 27.4% (95% CI, 18.8-38.0%). Among patients receiving NACT, VTE occurred in 14.3% during NACT and in 16.7% during ongoing chemotherapy. Postoperative and adjuvant treatment rates were less than 10.0%. Khorana score was a poor predictor of VTE, with 52.0% of intermediate-risk patients developing VTE. These findings highlight the need for improved VTE risk-reduction strategies, including larger studies to evaluate optimization of risk stratification and VTE prophylaxis during systemic therapy for advanced EC.\",\"PeriodicalId\":19483,\"journal\":{\"name\":\"Obstetrics and gynecology\",\"volume\":\"75 1\",\"pages\":\"\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrics and gynecology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/aog.0000000000005978\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrics and gynecology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/aog.0000000000005978","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

晚期子宫内膜癌（EC）患者有静脉血栓栓塞（VTE）的风险，尽管不同治疗阶段的风险尚不清楚。这项单机构回顾性研究评估了84例接受新辅助化疗（NACT, n=34）或辅助化疗（n=50）的III-IV期EC患者。静脉血栓栓塞总发生率为27.4% （95% CI, 18.8-38.0%）。在接受NACT治疗的患者中，静脉血栓栓塞发生率为14.3%，在持续化疗期间为16.7%。术后辅助治疗率均小于10.0%。Khorana评分不能很好地预测静脉血栓栓塞，52.0%的中危患者发生静脉血栓栓塞。这些发现强调了改进静脉血栓栓塞风险降低策略的必要性，包括更大规模的研究，以评估晚期EC全身治疗期间风险分层和静脉血栓栓塞预防的优化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Incidence and Timing of Venous Thromboembolism in Patients With Advanced Endometrial Cancer.

Patients with advanced endometrial cancer (EC) are at risk for venous thromboembolism (VTE), though risk by treatment phase remains unclear. This single-institution retrospective study evaluated 84 patients receiving neoadjuvant chemotherapy (NACT, n=34) or adjuvant chemotherapy (n=50) for stage III-IV EC. Overall VTE incidence was 27.4% (95% CI, 18.8-38.0%). Among patients receiving NACT, VTE occurred in 14.3% during NACT and in 16.7% during ongoing chemotherapy. Postoperative and adjuvant treatment rates were less than 10.0%. Khorana score was a poor predictor of VTE, with 52.0% of intermediate-risk patients developing VTE. These findings highlight the need for improved VTE risk-reduction strategies, including larger studies to evaluate optimization of risk stratification and VTE prophylaxis during systemic therapy for advanced EC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Obstetrics and gynecology 医学-妇产科学

CiteScore

11.10

自引率

4.20%

发文量

867

审稿时长

1 months

期刊介绍： "Obstetrics & Gynecology," affectionately known as "The Green Journal," is the official publication of the American College of Obstetricians and Gynecologists (ACOG). Since its inception in 1953, the journal has been dedicated to advancing the clinical practice of obstetrics and gynecology, as well as related fields. The journal's mission is to promote excellence in these areas by publishing a diverse range of articles that cover translational and clinical topics. "Obstetrics & Gynecology" provides a platform for the dissemination of evidence-based research, clinical guidelines, and expert opinions that are essential for the continuous improvement of women's health care. The journal's content is designed to inform and educate obstetricians, gynecologists, and other healthcare professionals, ensuring that they stay abreast of the latest developments and best practices in their field.